JP2023526495A5 - - Google Patents

Info

Publication number
JP2023526495A5
JP2023526495A5 JP2022571114A JP2022571114A JP2023526495A5 JP 2023526495 A5 JP2023526495 A5 JP 2023526495A5 JP 2022571114 A JP2022571114 A JP 2022571114A JP 2022571114 A JP2022571114 A JP 2022571114A JP 2023526495 A5 JP2023526495 A5 JP 2023526495A5
Authority
JP
Japan
Prior art keywords
sars
cov
sequence
seq
spike
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033275 external-priority patent/WO2021236854A1/en
Publication of JP2023526495A publication Critical patent/JP2023526495A/ja
Publication of JP2023526495A5 publication Critical patent/JP2023526495A5/ja
Pending legal-status Critical Current

Links

JP2022571114A 2020-05-19 2021-05-19 SARS-CoV-2ワクチン Pending JP2023526495A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063027283P 2020-05-19 2020-05-19
US63/027,283 2020-05-19
US202063047789P 2020-07-02 2020-07-02
US63/047,789 2020-07-02
US202163139292P 2021-01-19 2021-01-19
US63/139,292 2021-01-19
PCT/US2021/033275 WO2021236854A1 (en) 2020-05-19 2021-05-19 Sars-cov-2 vaccines

Publications (2)

Publication Number Publication Date
JP2023526495A JP2023526495A (ja) 2023-06-21
JP2023526495A5 true JP2023526495A5 (cg-RX-API-DMAC7.html) 2024-05-27

Family

ID=78707614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571114A Pending JP2023526495A (ja) 2020-05-19 2021-05-19 SARS-CoV-2ワクチン

Country Status (9)

Country Link
US (1) US20230330215A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153730A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526495A (cg-RX-API-DMAC7.html)
KR (1) KR20230025670A (cg-RX-API-DMAC7.html)
CN (1) CN116437951A (cg-RX-API-DMAC7.html)
AU (1) AU2021273827A1 (cg-RX-API-DMAC7.html)
CA (1) CA3178115A1 (cg-RX-API-DMAC7.html)
IL (1) IL297795A (cg-RX-API-DMAC7.html)
WO (1) WO2021236854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
JP7895943B2 (ja) * 2020-11-12 2026-07-28 ティースキャン セラピューティクス インコーポレイテッド Sars-cov-2免疫優性ペプチドの構築物及びその使用
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20240409587A1 (en) * 2021-04-12 2024-12-12 La Jolla Institute For Immunology Coronavirus T Cell Epitopes and Uses Thereof
US20240269267A1 (en) * 2021-06-03 2024-08-15 The Wistar Institute Of Anatomy And Biology Synthetic dna vaccine immunogenic improvements
WO2022268916A2 (en) * 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023081936A2 (en) * 2021-11-08 2023-05-11 Gritstone Bio, Inc. Sars-cov-2 vaccines
CN116212012A (zh) * 2021-12-02 2023-06-06 上海泽润生物科技有限公司 复合佐剂以及包含它的疫苗制剂
WO2023100159A2 (en) * 2021-12-03 2023-06-08 Kashiv Biosciences, Llc Multicistron expression vector for covid-19 vaccine
WO2023146791A1 (en) * 2022-01-27 2023-08-03 Academia Sinica Peptide-mediated delivery of active agents
CN114907453B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
CA3259040A1 (en) * 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2024026553A1 (en) * 2022-08-03 2024-02-08 Centre Hospitalier De L'université De Montréal Novel antigenic epitope against sars-cov-2 and uses thereof
WO2024061188A1 (zh) * 2022-09-19 2024-03-28 百奥泰生物制药股份有限公司 一种冠状病毒多价疫苗及其应用
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114477B2 (ja) * 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用

Similar Documents

Publication Publication Date Title
JP2021525076A5 (cg-RX-API-DMAC7.html)
JP2023541108A5 (cg-RX-API-DMAC7.html)
US20230330215A1 (en) Sars-cov-2 vaccines
JP2022539417A5 (cg-RX-API-DMAC7.html)
JP2023521662A5 (cg-RX-API-DMAC7.html)
JP2022512912A5 (cg-RX-API-DMAC7.html)
JP2021524247A5 (cg-RX-API-DMAC7.html)
JP2022534282A5 (cg-RX-API-DMAC7.html)
JP2021525076A (ja) 共有抗原
JP2021524247A (ja) 免疫チェックポイント阻害剤の共発現ベクター
JP2022512912A (ja) アルファウイルス新生抗原ベクター及びインターフェロン阻害因子
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2020518648A (ja) アルファウイルス新生抗原ベクター
JP2023523413A5 (cg-RX-API-DMAC7.html)
JP2023523414A5 (cg-RX-API-DMAC7.html)
US20250121052A1 (en) Sars-cov-2 vaccines
JP2024503108A5 (cg-RX-API-DMAC7.html)
EP4281110A2 (en) Modified alphavirus vectors
JP2024542126A5 (cg-RX-API-DMAC7.html)
CN120888569A (zh) 一种自复制mRNA疫苗及其制备方法和用途
JP2023510544A (ja) ヘルペスウイルス糖タンパク質dと融合したb型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法
JP2023553014A5 (cg-RX-API-DMAC7.html)
US20240238412A1 (en) Pancoronavirus vaccines
WO2026030253A1 (en) Human papillomavirus (hpv) vaccines
CN118302195A (zh) 泛冠状病毒疫苗